SO
SOPH.US Sophia Genetics SA
- Market cap
- USD 637M
- P/E
- -
- P/B
- 10.28x
- ROE
- -120.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SOPH.US undervalued?
Graham numberThe Graham number of Sophia Genetics SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sophia Genetics SA fundamental analysis
No fundamental analysis for Sophia Genetics SA yet.
Sophia Genetics SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sophia Genetics SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry co…
Full company profileSophia Genetics SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sophia Genetics SA annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 25.4M | 28.4M | 40.5M | 47.6M | 62.4M | 65.2M | 77.3M | 92.4M |
| Gross Profit | 17.8M | 17.7M | 25.2M | 31.3M | 42.9M | 43.9M | 47.8M | 61.0M |
| Operating Income | -32.3M | -37.4M | -71.5M | -87.8M | -74.8M | -66.6M | -70.9M | -73.5M |
| EBITDA | -30.7M | -38.0M | -69.2M | -81.4M | -69.6M | -50.8M | -64.4M | -67.7M |
| Net Income | -33.8M | -39.3M | -73.7M | -87.4M | -79.0M | -62.5M | -79.0M | -82.6M |
| EPS | -0.53 | -0.82 | -1.33 | -1.36 | -1.22 | -0.95 | -1.17 | -0.97 |
| Balance Sheet | ||||||||
| Total Assets | 51.7M | 132M | 320M | 244M | 206M | 155M | 163M | 185M |
| Total Liabilities | 29.4M | 31.6M | 44.8M | 43.7M | 54.7M | 58.8M | 116M | 116M |
| Shareholders' Equity | 22.3M | 101M | 275M | 200M | 151M | 96.5M | 47.1M | 68.4M |
| Cash & Short-term Investments | 18.4M | 97.3M | 265M | 179M | 123M | 80.2M | 70.3M | 93.7M |
| Total Debt | 8.46M | 7.25M | 13.1M | 16.7M | 18.6M | 30.0M | 63.0M | 61.0M |
| Cash Flow | ||||||||
| Operating Cash Flow | -31.7M | -31.7M | -57.9M | -70.1M | -48.6M | -42.8M | -38.0M | -44.5M |
| Capital Expenditure | 3.03M | 3.20M | 6.67M | 10.4M | 9.23M | 8.18M | 574K | 7.86M |
| Free Cash Flow | -34.7M | -34.9M | -64.6M | -80.5M | -57.8M | -51.0M | -38.6M | -52.3M |
| Ratios | ||||||||
| ROE | -151.8% | -39.1% | -26.8% | -43.7% | -52.2% | -64.8% | -167.6% | -120.7% |
| ROA | -65.4% | -29.8% | -23.0% | -35.9% | -38.3% | -40.2% | -48.3% | -44.7% |
| Net Profit Margin | -133.2% | -138.5% | -182.1% | -183.9% | -126.6% | -95.9% | -102.2% | -89.4% |
| Debt to Equity | 0.38x | 0.07x | 0.05x | 0.08x | 0.12x | 0.31x | 1.34x | 0.89x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sophia Genetics SA dividends
Sophia Genetics SA has not paid dividends in the last 7 fiscal years.
Who owns Sophia Genetics SA
- Insiders 7.22%
- Institutions 66.18%
- Public & others 26.60%
- Shares outstanding 85.7M
- Free float 66.2M
Top funds holding SOPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Columbia Small Cap Growth Inst | 2.15M | 2.50% | 0.00% | Sep 2026 |
| Royce Micro-Cap Trust | 941K | 1.10% | +4.80% | Sep 2026 |
| Principal SmallCap R5 | 879K | 1.03% | 0.00% | Sep 2026 |
| Royce Small-Cap Opportunity Invmt | 755K | 0.88% | +14.34% | Sep 2026 |
| FTGF RY US SmCp Opp A USD Dis(A) | 654K | 0.76% | -4.03% | Oct 2026 |
| Royce Small-Cap Trust | 498K | 0.58% | +61.04% | Sep 2026 |
| Royce Small-Cap Fund Invmt | 423K | 0.49% | +61.05% | Sep 2026 |
| Royce Micro-Cap Invmt | 404K | 0.47% | +7.03% | Sep 2026 |
| 1290 Essex Small Cap Growth I | 162K | 0.19% | +0.53% | Sep 2026 |
| Columbia VP Small Company Growth 1 | 146K | 0.17% | +72.23% | Aug 2026 |
| Royce Capital Micro-Cap Inv | 134K | 0.16% | +7.38% | Sep 2026 |
| EdR SICAV Tech for Tomorrow CR EUR | 120K | 0.14% | -20.00% | Sep 2026 |
| Principal VC SmallCap 1 | 96.1K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite ETF | 57.7K | 0.07% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 46.4K | 0.05% | 0.00% | Oct 2026 |
| IST America Small Mid Caps Kat III | 33.1K | 0.04% | +41.41% | Oct 2026 |
| North Square Kennedy MicroCap I | 27.2K | 0.03% | +0.82% | Jun 2026 |
| Fidelity Nasdaq Composite Index | 27.1K | 0.03% | -37.75% | Aug 2026 |
| Venerable US Small Cap V | 25.0K | 0.03% | 0.00% | Oct 2026 |
| Harbor Health Care ETF | 24.7K | 0.03% | 0.00% | Oct 2026 |
Top institutions holding SOPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Generation Investment Management LLP | 6.79M | 7.93% | 0.00% | Jun 2026 |
| AIGH Capital Management, LLC | 3.95M | 4.62% | 0.00% | Jun 2026 |
| Akre Capital Management, LLC | 3.72M | 4.34% | 0.00% | Jun 2026 |
| Royce & Associates, LP | 3.38M | 3.95% | +86.19% | Jun 2026 |
| Ameriprise Financial Inc | 2.22M | 2.59% | 0.00% | Jun 2026 |
| Banque Pictet & Cie SA | 2.21M | 2.58% | 0.00% | Jun 2026 |
| Principal Financial Group Inc | 2.15M | 2.52% | -8.87% | Sep 2026 |
| Awm Investment Company Inc | 1.70M | 1.98% | 0.00% | Jun 2026 |
| Soleus Capital Management, L.P. | 1.57M | 1.83% | -15.41% | Jun 2026 |
| Silvercrest Asset Management Group LLC | 1.43M | 1.67% | 0.00% | Jun 2026 |
| Alta Wealth Advisors LLC | 1.26M | 1.47% | -10.64% | Sep 2026 |
| Kennedy Capital Management Inc | 918K | 1.07% | -1.06% | Jun 2026 |
| Archon Capital Management LLC | 691K | 0.81% | +56.64% | Jun 2026 |
| Essex Investment Management Company, LLC | 663K | 0.77% | -4.24% | Jun 2026 |
| Ensign Peak Advisors Inc | 445K | 0.52% | -0.07% | Jun 2026 |
| Hodges Capital Management Inc | 409K | 0.48% | -6.14% | Jun 2026 |
| Acadian Asset Management LLC | 347K | 0.40% | +1,433.67% | Sep 2026 |
| Renaissance Technologies Corp | 271K | 0.32% | +139.10% | Sep 2026 |
| Pictet & Cie (Europe) SA | 255K | 0.30% | 0.00% | Sep 2026 |
| Legato Capital Management LLC | 223K | 0.26% | +3.18% | Jun 2026 |
Sophia Genetics SA company profile
- Company name
- Sophia Genetics SA
- Ticker
- SOPH.US
- ISIN
- CH1125843347
- Exchange
- USA Stocks
- Listed since
- Jul 23, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 415
- Fiscal year end
- December
- Address
- La PiEce 12, Rolle, Switzerland, 1180
- Phone
- 41 21 694 10 60
- Website
- sophiagenetics.com
About Sophia Genetics SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.
Sophia Genetics SA management
9- Dr. Jurgi Camblong M.B.A., Ph.D.Co-Founder & Executive Chairman · born 1978
- Mr. Ross Jordan Muken B.Sc.CEO & Director · born 1980
- Mr. George A. Cardoza M.B.A.Executive VP & CFO · born 1962
- Mr. Abhimanyu VermaEVP & Chief Technology Officer
- Dr. Zhenyu Xu Ph.D.Executive VP & Chief Scientific Officer · born 1983
- Kellen SangerHead of Strategy and Investor Relations
- Mr. Daan van Well L.L.M., M.B.A.Executive VP and Chief Legal & Compliance Officer · born 1975
- Mr. Kevin PuylaertSVP & Chief Sales Officer
- Ms. Manuela Da Silva Valente B.A.Executive VP & Chief People Officer · born 1971